Pramlintide

Pramlintide is a synthetic analogue of human amylin, also known as islet amyloid polypeptide, a small peptide hormone that pancreatic beta cells release together with insulin in response to food ^[1][2]. Native amylin tends to clump and is impractical as a medicine, so in pramlintide several amino acids are substituted to create a stable, water-soluble peptide that keeps amylin's biological actions; it is classed as an amylin analogue or amylinomimetic ^[1].

The drug was approved by the United States Food and Drug Administration in 2005 under the brand name Symlin, as an add-on to mealtime insulin for adults with type 1 or type 2 diabetes. It holds a notable place in diabetes care as the first new agent approved to lower blood sugar in type 1 diabetes since the introduction of insulin in the 1920s ^[3]. It is given by subcutaneous injection and, because it is not chemically compatible with insulin in the same syringe, must be injected separately.

In clinical use pramlintide is added to insulin to smooth the after-meal glucose rise. Trials show it reduces post-meal glucose, produces modest reductions in HbA1c, and commonly leads to lower mealtime insulin requirements and some weight loss ^[1][2]. A pooled analysis of overweight and obese people with insulin-treated type 2 diabetes found meaningful weight reduction with pramlintide compared with placebo ^[4]. The underlying rationale is that amylin is deficient in type 2 diabetes and essentially absent in type 1, so the drug restores a missing hormonal signal ^[2].

Pramlintide is a prescription medicine. Its most common adverse effect is nausea, which tends to lessen over time, and because it is used with insulin it raises the risk of hypoglycaemia; for this reason mealtime insulin doses are usually reduced when pramlintide is started, and close glucose monitoring is advised ^[1][3].

Strong evidence

⚠️ THE APPROVAL TRIAL WAS NULL ON ITS GLYCAEMIC ENDPOINT, and that frames everything else. In type 1 diabetes on intensive insulin, HbA1c fell 0.5 percent on pramlintide and 0.5 percent on placebo, no difference at all; what separated the arms was weight, at minus 1.3 against plus 1.2 kilograms, and insulin use, down 28 percent against 4 percent ^[11]. Across the whole evidence base the placebo-corrected HbA1c effect is 0.2 to 0.4 percent ^[15], and a 2021 network meta-analysis of 58 type 1 adjunct trials does not list pramlintide among the drugs that reduced HbA1c against placebo at all.

The weight effect is real but should be described precisely. Placebo-corrected weight change is about 1.2 kilograms at 52 weeks in type 1 and 2.1 in type 2 ^[10][12]. ⚠️ Most of that is avoided insulin-associated weight GAIN rather than weight loss, which one trial makes explicit: 0.0 kilograms on pramlintide against plus 4.7 on prandial insulin ^[13]. In obesity without diabetes the placebo-corrected loss was 3.6 kilograms over 16 weeks ^[14].

⚠️ Two pieces of history are worth carrying. An FDA advisory committee voted against recommending approval in 2001, and approval required a dedicated safety and titration study; that study is the one that then showed no HbA1c benefit. The European marketing application was withdrawn in 2002 and pramlintide was never approved in Europe.

⚠️ And it is now discontinued. The FDA drug database records all three Symlin products with a marketing status of discontinued. A preference study puts the commercial failure in context: asked to choose among adjunct profiles, 83 percent of people with type 1 diabetes preferred a low-dose SGLT-inhibitor profile and 6 percent chose pramlintide.

⚠️ The current amylin drugs are not this molecule. Cagrilintide, petrelintide and eloralintide are different peptides with different receptor profiles and weekly dosing; no pramlintide data transfers to them. Pramlintide's own live research is academic closed-loop insulin work and co-formulation engineering aimed at the two-injection problem its proline substitutions created.

The biggest risk is severe hypoglycemia when combined with insulin, which is why insulin doses are usually reduced when starting it. Nausea is very common early on and usually fades with slow titration. It carries a boxed warning about insulin-associated hypoglycemia and must be used under medical supervision; it is injected separately from insulin.

⚠️ THE BOXED WARNING IS TIME-BOUNDED, AND THAT IS THE MOST USEFUL THING TO KNOW ABOUT IT. Severe hypoglycaemia with pramlintide is concentrated in the first three months. In type 1 diabetes the medically-assisted event rate is 0.50 per patient-year on the drug against 0.19 on placebo during months 0 to 3, and 0.27 against 0.24 thereafter: about 2.6 times placebo at the start and at parity by six months. Per-trial figures show the same shape more starkly, with roughly four times the placebo rate at week 4 converging by week 52.

That hazard is mitigable, and one trial demonstrated it directly. The study that mandated a 30 to 50 percent reduction in mealtime insulin at initiation cut the week-4 event rate to a non-significant 0.75 against 0.42 ^[11]. The label now requires exactly that reduction, and a starting dose of 15 micrograms in type 1 and 60 in type 2.

Gastrointestinal effects are the other main issue and they are transient. Nausea occurs in 48 percent in type 1 and 28 percent in type 2 against 17 and 12 percent on placebo, and falls substantially with time; in one obesity programme nausea ran at 9 to 29 percent over the first four months and 0 to 9 percent during the following eight, with twelve withdrawals for nausea in the first phase and none in the second.

Pooled cardiovascular data across about 2,000 patients showed no signal, with major adverse cardiac events at 4.7 percent against 4.5 percent.

Pharmacokinetics are complete: subcutaneous bioavailability 30 to 40 percent, peak at about 20 minutes, half-life around 48 minutes, roughly 40 percent unbound, cleared mainly by the kidney, with an active metabolite. No dose adjustment is needed down to a creatinine clearance of 15. ⚠️ One database annotation labels the 30 percent figure as oral bioavailability; pramlintide is injectable only and is not orally bioavailable.

Pramlintide's interactions follow directly from what it does. It slows gastric emptying markedly, so oral drugs taken around the same time arrive later. A crossover study in type 2 diabetes measured this with acetaminophen and found peak concentration fell by 14% to 29% and time to peak lengthened by roughly an hour, while total absorption was unchanged. For anything that needs a fast onset, that delay is the difference between working and not.

The dangerous interaction is with insulin. Pramlintide is used alongside mealtime insulin and carries a boxed warning for severe hypoglycaemia, which typically appears within three hours of injection and has caused loss of consciousness and motor vehicle accidents. The risk is highest when the accompanying insulin has not been accounted for.

Other agents that alter gastrointestinal motility compound the effect: anticholinergics such as atropine slow transit further, while alpha glucosidase inhibitors like acarbose already delay carbohydrate absorption, so that combination is generally avoided.

Checking a whole stack? Run it through interactions + stacks.